{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:25:54Z","timestamp":1793676354469,"version":"4.5.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-25467534"],"award-info":[{"award-number":["RS-2025-25467534"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1324"],"award-info":[{"award-number":["HI14C1324"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072434"],"award-info":[{"award-number":["RS-2022-NR072434"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00259-026-08165-x","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:52:37Z","timestamp":1788936757000},"page":"7936-7954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["APOE4-dependent cholinergic\/dopaminergic contributions to clinical symptoms across Alzheimer\u2019s disease spectrum: A retrospective observational study"],"prefix":"10.1007","volume":"53","author":[{"given":"Sungwoo","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donggeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hee","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-gun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mijin","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0187-8440","authenticated-orcid":false,"given":"Byoung Seok","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"8165_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00702-021-02449-2","volume":"129","author":"KA Jellinger","year":"2022","unstructured":"Jellinger KA. Recent update on the heterogeneity of the Alzheimer\u2019s disease spectrum. J Neural Transm. 2022;129:1\u201324. https:\/\/doi.org\/10.1007\/s00702-021-02449-2.","journal-title":"J Neural Transm"},{"key":"8165_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trci.2016.09.002","volume":"3","author":"GD Rabinovici","year":"2017","unstructured":"Rabinovici GD, Carrillo MC, Forman M, DeSanti S, Miller DS, Kozauer N, et al. Multiple comorbid neuropathologies in the setting of Alzheimer\u2019s disease neuropathology and implications for drug development. Alzheimers Dement (N Y). 2017;3:83\u201391. https:\/\/doi.org\/10.1016\/j.trci.2016.09.002.","journal-title":"Alzheimers Dement (N Y)"},{"key":"8165_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503\u201327. https:\/\/doi.org\/10.1093\/brain\/awz099.","journal-title":"Brain"},{"key":"8165_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27:871\u201381. https:\/\/doi.org\/10.1038\/s41591-021-01309-6.","journal-title":"Nat Med"},{"key":"8165_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13195-020-00712-4","volume":"12","author":"S Emrani","year":"2020","unstructured":"Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer\u2019s disease: a systematic review. Alzheimers Res Ther. 2020;12:141. https:\/\/doi.org\/10.1186\/s13195-020-00712-4.","journal-title":"Alzheimers Res Ther"},{"key":"8165_CR6","doi-asserted-by":"publisher","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology. 2021;96:e650\u201361. https:\/\/doi.org\/10.1212\/WNL.0000000000011270.","journal-title":"Neurology"},{"key":"8165_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/wnl.57.8.1461","volume":"57","author":"M Hashimoto","year":"2001","unstructured":"Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, et al. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer\u2019s disease. Neurology. 2001;57:1461\u20136. https:\/\/doi.org\/10.1212\/wnl.57.8.1461.","journal-title":"Neurology"},{"key":"8165_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1212\/wnl.53.8.1825","volume":"53","author":"C Geroldi","year":"1999","unstructured":"Geroldi C, Pihlajam\u00e4ki M, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, et al. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology. 1999;53:1825\u201332. https:\/\/doi.org\/10.1212\/wnl.53.8.1825.","journal-title":"Neurology"},{"key":"8165_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"key":"8165_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-018-0403-x","volume":"10","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, J\u00f6gi J, et al. Greater tau load and reduced cortical thickness in APOE \u03b54-negative Alzheimer\u2019s disease: a cohort study. Alzheimers Res Ther. 2018;10:77. https:\/\/doi.org\/10.1186\/s13195-018-0403-x.","journal-title":"Alzheimers Res Ther"},{"key":"8165_CR11","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1038\/s41380-022-01531-9","volume":"27","author":"DW Sirkis","year":"2022","unstructured":"Sirkis DW, Bonham LW, Johnson TP, La Joie R, Yokoyama JS. Dissecting the clinical heterogeneity of early-onset Alzheimer\u2019s disease. Mol Psychiatry. 2022;27:2674\u201388. https:\/\/doi.org\/10.1038\/s41380-022-01531-9.","journal-title":"Mol Psychiatry"},{"key":"8165_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01359-x","author":"S Saggu","year":"2024","unstructured":"Saggu S, Bai A, Aida M, Rehman H, Pless A, Ware D, et al. Monoamine alterations in Alzheimer\u2019s disease and their implications in comorbid neuropsychiatric symptoms. GeroScience. 2024. https:\/\/doi.org\/10.1007\/s11357-024-01359-x.","journal-title":"GeroScience"},{"key":"8165_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04333-y","author":"E Akyuz","year":"2024","unstructured":"Akyuz E, Arulsamy A, Aslan FS, Saris\u00f6zen B, Guney B, Hekimoglu A, et al. An Expanded Narrative Review of Neurotransmitters on Alzheimer\u2019s Disease: The Role of Therapeutic Interventions on Neurotransmission. Mol Neurobiol. 2024. https:\/\/doi.org\/10.1007\/s12035-024-04333-y.","journal-title":"Mol Neurobiol"},{"key":"8165_CR14","doi-asserted-by":"publisher","unstructured":"Chen ZR, Huang JB, Yang SL, Hong FF. Role of Cholinergic Signaling in Alzheimer\u2019s Disease. Molecules. 2022;27. https:\/\/doi.org\/10.3390\/molecules27061816.","DOI":"10.3390\/molecules27061816"},{"key":"8165_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/brain\/awy040","volume":"141","author":"DL Sultzer","year":"2018","unstructured":"Sultzer DL. Cognitive ageing and Alzheimer\u2019s disease: the cholinergic system redux. Brain. 2018;141:626\u20138. https:\/\/doi.org\/10.1093\/brain\/awy040.","journal-title":"Brain"},{"key":"8165_CR16","doi-asserted-by":"publisher","first-page":"105393","DOI":"10.1016\/j.neubiorev.2023.105393","volume":"154","author":"M Mieling","year":"2023","unstructured":"Mieling M, Meier H, Bunzeck N. Structural degeneration of the nucleus basalis of Meynert in mild cognitive impairment and Alzheimer\u2019s disease - Evidence from an MRI-based meta-analysis. Neurosci Biobehav Rev. 2023;154:105393. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105393.","journal-title":"Neurosci Biobehav Rev"},{"key":"8165_CR17","doi-asserted-by":"publisher","first-page":"105192","DOI":"10.1016\/j.neubiorev.2023.105192","volume":"150","author":"AS Berry","year":"2023","unstructured":"Berry AS, Harrison TM. New perspectives on the basal forebrain cholinergic system in Alzheimer\u2019s disease. Neurosci Biobehav Rev. 2023;150:105192. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105192.","journal-title":"Neurosci Biobehav Rev"},{"key":"8165_CR18","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.ajpath.2011.07.044","volume":"179","author":"L Vana","year":"2011","unstructured":"Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI. Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer\u2019s disease. Am J Pathol. 2011;179:2533\u201350. https:\/\/doi.org\/10.1016\/j.ajpath.2011.07.044.","journal-title":"Am J Pathol"},{"key":"8165_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00401-006-0146-9","volume":"113","author":"J Attems","year":"2007","unstructured":"Attems J, Quass M, Jellinger KA. Tau and \u03b1-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol. 2007;113:53\u201362. https:\/\/doi.org\/10.1007\/s00401-006-0146-9.","journal-title":"Acta Neuropathol"},{"key":"8165_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/JAD-131289","volume":"39","author":"J Horvath","year":"2014","unstructured":"Horvath J, Burkhard PR, Herrmann FR, Bouras C, K\u00f6vari E. Neuropathology of Parkinsonism in Patients with Pure Alzheimer\u2019s Disease. J Alzheimer\u2019s Disease. 2014;39:115\u201320. https:\/\/doi.org\/10.3233\/JAD-131289.","journal-title":"J Alzheimer\u2019s Disease"},{"key":"8165_CR21","doi-asserted-by":"publisher","first-page":"14727","DOI":"10.1038\/ncomms14727","volume":"8","author":"A Nobili","year":"2017","unstructured":"Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer\u2019s disease. Nat Commun. 2017;8:14727. https:\/\/doi.org\/10.1038\/ncomms14727.","journal-title":"Nat Commun"},{"key":"8165_CR22","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1111\/ene.15995","volume":"30","author":"S Kang","year":"2023","unstructured":"Kang S, Jeon S, Lee YG, Ye BS. Striatal dopamine transporter uptake, parkinsonism and cognition in Alzheimer\u2019s disease. Eur J Neurol. 2023;30:3105\u201313. https:\/\/doi.org\/10.1111\/ene.15995.","journal-title":"Eur J Neurol"},{"key":"8165_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.nbd.2005.12.016","volume":"22","author":"MKP Lai","year":"2006","unstructured":"Lai MKP, Tsang SWY, Garcia-Alloza M, Minger SL, Nicoll JAR, Esiri MM, et al. Selective effects of the APOE \u03b54 allele on presynaptic cholinergic markers in the neocortex of Alzheimer\u2019s disease. Neurobiol Dis. 2006;22:555\u201361. https:\/\/doi.org\/10.1016\/j.nbd.2005.12.016.","journal-title":"Neurobiol Dis"},{"key":"8165_CR24","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1038\/s41467-024-48490-z","volume":"15","author":"A Wearn","year":"2024","unstructured":"Wearn A, Tremblay SA, Tardif CL, Leppert IR, Gauthier CJ, Baracchini G, et al. Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status. Nat Commun. 2024;15:4706. https:\/\/doi.org\/10.1038\/s41467-024-48490-z.","journal-title":"Nat Commun"},{"key":"8165_CR25","doi-asserted-by":"publisher","first-page":"12260","DOI":"10.1073\/pnas.92.26.12260","volume":"92","author":"J Poirier","year":"1995","unstructured":"Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92:12260\u20134. https:\/\/doi.org\/10.1073\/pnas.92.26.12260.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8165_CR26","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1038\/s41467-020-18198-x","volume":"11","author":"TE Goldberg","year":"2020","unstructured":"Goldberg TE, Huey ED, Devanand DP. Association of APOE e2 genotype with Alzheimer\u2019s and non-Alzheimer\u2019s neurodegenerative pathologies. Nat Commun. 2020;11:4727. https:\/\/doi.org\/10.1038\/s41467-020-18198-x.","journal-title":"Nat Commun"},{"key":"8165_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s40478-022-01487-5","volume":"10","author":"A Raunio","year":"2022","unstructured":"Raunio A, Kivist\u00f6 V, Kero M, Tuimala J, Savola S, Oinas M, et al. Distribution of Lewy-related pathology in the brain, spinal cord, and periphery: the population-based Vantaa 85\u2009+\u2009study. Acta Neuropathol Commun. 2022;10:178. https:\/\/doi.org\/10.1186\/s40478-022-01487-5.","journal-title":"Acta Neuropathol Commun"},{"key":"8165_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00401-019-02071-3","volume":"138","author":"A Raunio","year":"2019","unstructured":"Raunio A, Kaivola K, Tuimala J, Kero M, Oinas M, Polvikoski T, et al. Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85. Acta Neuropathol. 2019;138:771\u201382. https:\/\/doi.org\/10.1007\/s00401-019-02071-3.","journal-title":"Acta Neuropathol"},{"key":"8165_CR29","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1038\/s41467-024-49402-x","volume":"15","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek SE, Vogel JW, Collij LE, Serrano GE, Tremblay C, Young AL, et al. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type \u03b1-synuclein pathology. Nat Commun. 2024;15:5133. https:\/\/doi.org\/10.1038\/s41467-024-49402-x.","journal-title":"Nat Commun"},{"key":"8165_CR30","doi-asserted-by":"publisher","first-page":"110177","DOI":"10.1016\/j.compbiomed.2025.110177","volume":"192","author":"HJ Son","year":"2025","unstructured":"Son HJ, Kim C, Choi HJ. Comprehensive evaluation of early-phase FP-CIT PET as a substitute for brain FDG PET in parkinsonism. Comput Biol Med. 2025;192:110177. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110177.","journal-title":"Comput Biol Med"},{"key":"8165_CR31","doi-asserted-by":"publisher","first-page":"e70920","DOI":"10.1002\/alz.70920","volume":"21","author":"S Kang","year":"2025","unstructured":"Kang S, Jeon S, Kim Y, Jeon SH, Choi M, Lee YG, et al. Putaminal hypermetabolism identifies Lewy body co-pathology in Alzheimer\u2019s disease. Alzheimers Dement. 2025;21:e70920. https:\/\/doi.org\/10.1002\/alz.70920.","journal-title":"Alzheimers Dement"},{"key":"8165_CR32","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1002\/alz.13379","volume":"19","author":"Y-g Lee","year":"2023","unstructured":"Lee Y-g, Jeon S, Kang SW, Ye BS. Effects of amyloid beta and dopaminergic depletion on perfusion and clinical symptoms. Alzheimer\u2019s Dement. 2023;19:5719\u201329. https:\/\/doi.org\/10.1002\/alz.13379.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8165_CR33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1017\/S1041610208007709","volume":"20","author":"SJ Colloby","year":"2008","unstructured":"Colloby SJ, Firbank MJ, Pakrasi S, Lloyd JJ, Driver I, McKeith IG, et al. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer\u2019s disease and dementia with Lewy bodies. Int Psychogeriatr. 2008;20:1124\u201340. https:\/\/doi.org\/10.1017\/S1041610208007709.","journal-title":"Int Psychogeriatr"},{"key":"8165_CR34","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/mds.29138","volume":"37","author":"J Lu","year":"2022","unstructured":"Lu J, Ge J, Chen K, Sun Y, Liu F, Yu H, et al. Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias. Mov Disord. 2022;37:1861\u201371. https:\/\/doi.org\/10.1002\/mds.29138.","journal-title":"Mov Disord"},{"key":"8165_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"8165_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"8165_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1212\/WNL.62.2.181","volume":"62","author":"TJ Ferman","year":"2004","unstructured":"Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB fluctuations Neurol. 2004;62:181. https:\/\/doi.org\/10.1212\/WNL.62.2.181.","journal-title":"DLB fluctuations Neurol"},{"key":"8165_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1212\/WNL.0b013e3181ca017d","volume":"74","author":"E Adriana","year":"2010","unstructured":"Adriana E, Noor A-H, James EG. Effect of cognitive fluctuation on neuropsychological performance in aging and dementia. Neurology. 2010;74:210. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ca017d.","journal-title":"Neurology"},{"key":"8165_CR39","unstructured":"Kang Y, Na D. Seoul Neuropsychological Screening Battery (SNSB). Human Brain Research & Consulting Co. Incheon; 2003."},{"key":"8165_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/089198873258818","volume":"17","author":"SJ Kang","year":"2004","unstructured":"Kang SJ, Choi SH, Lee BH, Jeong Y, Hahm DS, Han IW, et al. Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). J Geriatr Psychiatry Neurol. 2004;17:32\u20135. https:\/\/doi.org\/10.1177\/089198873258818.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"8165_CR41","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.neuroimage.2008.05.055","volume":"42","author":"L Zaborszky","year":"2008","unstructured":"Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. NeuroImage. 2008;42:1127\u201341. https:\/\/doi.org\/10.1016\/j.neuroimage.2008.05.055.","journal-title":"NeuroImage"},{"key":"8165_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ima.20277","volume":"21","author":"S Jeon","year":"2011","unstructured":"Jeon S, Yoon U, Park JS, Seo SW, Kim JH, Kim ST, et al. Fully Automated Pipeline for Quantification and Localization of White Matter Hyperintensity in Brain Magnetic Resonance Image. Int J Imag Syst Tech. 2011;21:193\u2013200. https:\/\/doi.org\/10.1002\/ima.20277.","journal-title":"Int J Imag Syst Tech"},{"key":"8165_CR43","doi-asserted-by":"publisher","first-page":"A121","DOI":"10.1038\/jcbfm.1991.47","volume":"11","author":"JR Moeller","year":"1991","unstructured":"Moeller JR, Strother SC. A Regional Covariance Approach to the Analysis of Functional Patterns in Positron Emission Tomographic Data. J Cereb Blood Flow Metabolism. 1991;11:A121\u201335. https:\/\/doi.org\/10.1038\/jcbfm.1991.47.","journal-title":"J Cereb Blood Flow Metabolism"},{"key":"8165_CR44","doi-asserted-by":"publisher","first-page":"116189","DOI":"10.1016\/j.neuroimage.2019.116189","volume":"206","author":"ET Rolls","year":"2020","unstructured":"Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. NeuroImage. 2020;206:116189. https:\/\/doi.org\/10.1016\/j.neuroimage.2019.116189.","journal-title":"NeuroImage"},{"key":"8165_CR45","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.neuroimage.2010.09.025","volume":"54","author":"BB Avants","year":"2011","unstructured":"Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. NeuroImage. 2011;54:2033\u201344. https:\/\/doi.org\/10.1016\/j.neuroimage.2010.09.025.","journal-title":"NeuroImage"},{"key":"8165_CR46","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroimage.2011.02.046","volume":"56","author":"B Patenaude","year":"2011","unstructured":"Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage. 2011;56:907\u201322. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.02.046.","journal-title":"NeuroImage"},{"key":"8165_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neurobiolaging.2018.08.007","volume":"72","author":"YG Lee","year":"2018","unstructured":"Lee YG, Jeon S, Yoo HS, Chung SJ, Lee SK, Lee PH, et al. Amyloid-beta-related and unrelated cortical thinning in dementia with Lewy bodies. Neurobiol Aging. 2018;72:32\u20139. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.08.007.","journal-title":"Neurobiol Aging"},{"key":"8165_CR48","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374. https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004.","journal-title":"Alzheimers Dement"},{"key":"8165_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jnen\/63.2.159","volume":"63","author":"EJG Dubelaar","year":"2004","unstructured":"Dubelaar EJG, Verwer RWH, Hofman MA, Van Heerikhuize JJ, Ravid R, Swaab DF. ApoE \u025b4 Genotype Is Accompanied by Lower Metabolic Activity in Nucleus Basalis of Meynert Neurons in Alzheimer Patients and Controls as Indicated by the Size of the Golgi Apparatus. J Neuropathology Experimental Neurol. 2004;63:159\u201369. https:\/\/doi.org\/10.1093\/jnen\/63.2.159.","journal-title":"J Neuropathology Experimental Neurol"},{"key":"8165_CR50","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1073\/pnas.95.19.11445","volume":"95","author":"A Salehi","year":"1998","unstructured":"Salehi A, Dubelaar EJ, Mulder M, Swaab DF. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer\u2019s disease is apolipoprotein E-type dependent. Proc Natl Acad Sci U S A. 1998;95:11445\u20139. https:\/\/doi.org\/10.1073\/pnas.95.19.11445.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8165_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s0304-3940(97)00872-0","volume":"239","author":"SJ Allen","year":"1997","unstructured":"Allen SJ, MacGowan SH, Tyler S, Wilcock GK, Robertson AG, Holden PH, et al. Reduced cholinergic function in normal and Alzheimer\u2019s disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett. 1997;239:33\u20136. https:\/\/doi.org\/10.1016\/s0304-3940(97)00872-0.","journal-title":"Neurosci Lett"},{"key":"8165_CR52","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1212\/01.wnl.0000128091.92139.0f","volume":"62","author":"P Tiraboschi","year":"2004","unstructured":"Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62:1977\u201383. https:\/\/doi.org\/10.1212\/01.wnl.0000128091.92139.0f.","journal-title":"Neurology"},{"key":"8165_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/wnl.54.2.403","volume":"54","author":"J Corey-Bloom","year":"2000","unstructured":"Corey-Bloom J, Tiraboschi P, Hansen LA, Alford M, Schoos B, Sabbagh MN, et al. E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer\u2019s disease. Neurology. 2000;54:403\u20136. https:\/\/doi.org\/10.1212\/wnl.54.2.403.","journal-title":"Neurology"},{"key":"8165_CR54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neulet.2006.08.061","volume":"408","author":"C Eggers","year":"2006","unstructured":"Eggers C, Herholz K, Kalbe E, Heiss WD. Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. Neurosci Lett. 2006;408:46\u201350. https:\/\/doi.org\/10.1016\/j.neulet.2006.08.061.","journal-title":"Neurosci Lett"},{"key":"8165_CR55","doi-asserted-by":"publisher","unstructured":"Lai Y-LL, Chen K, Lee T-W, Tso C-W, Lin H-H, Kuo L-W, et al. The Effect of the APOE-\u03b54 Allele on the Cholinergic Circuitry for Subjects With Different Levels of Cognitive Impairment. Front Neurol. 2021;12\u20132021. https:\/\/doi.org\/10.3389\/fneur.2021.651388.","DOI":"10.3389\/fneur.2021.651388"},{"key":"8165_CR56","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1177\/13872877251324080","volume":"104","author":"N Richter","year":"2025","unstructured":"Richter N, Breidenbach L, Schmieschek MH, Heiss WD, Fink GR, Onur OA. Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes. J Alzheimers Dis. 2025;104:1290\u2013300. https:\/\/doi.org\/10.1177\/13872877251324080.","journal-title":"J Alzheimers Dis"},{"key":"8165_CR57","doi-asserted-by":"publisher","first-page":"e1301","DOI":"10.1212\/WNL.0000000000010192","volume":"95","author":"SJ Teipel","year":"2020","unstructured":"Teipel SJ, Fritz H-C, Grothe MJ, Initiative ftAsDN. Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. Neurology. 2020;95:e1301\u201311. https:\/\/doi.org\/10.1212\/WNL.0000000000010192.","journal-title":"Neurology"},{"key":"8165_CR58","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1038\/s41380-025-02913-5","volume":"30","author":"A Pilotto","year":"2025","unstructured":"Pilotto A, Galli A, Sala A, Caminiti SP, Presotto L, Liguori C, et al. Dopaminergic deficits along the spectrum of Alzheimer\u2019s disease. Mol Psychiatry. 2025;30:3069\u201376. https:\/\/doi.org\/10.1038\/s41380-025-02913-5.","journal-title":"Mol Psychiatry"},{"key":"8165_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pneurobio.2008.09.004","volume":"86","author":"JA Grahn","year":"2008","unstructured":"Grahn JA, Parkinson JA, Owen AM. The cognitive functions of the caudate nucleus. Prog Neurobiol. 2008;86:141\u201355. https:\/\/doi.org\/10.1016\/j.pneurobio.2008.09.004.","journal-title":"Prog Neurobiol"},{"key":"8165_CR60","first-page":"1175","volume":"36","author":"CH van Dyck","year":"1995","unstructured":"van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med. 1995;36:1175\u201381.","journal-title":"J Nucl Med"},{"key":"8165_CR61","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00702-025-02960-w","volume":"132","author":"KA Jellinger","year":"2025","unstructured":"Jellinger KA. Vascular parkinsonism: an update. J Neural Transm. 2025;132:899\u2013919. https:\/\/doi.org\/10.1007\/s00702-025-02960-w.","journal-title":"J Neural Transm"},{"key":"8165_CR62","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1093\/brain\/aws211","volume":"135","author":"SJ Colloby","year":"2012","unstructured":"Colloby SJ, McParland S, O\u2019Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer\u2019s disease and Lewy body dementias. Brain. 2012;135:2798\u2013808. https:\/\/doi.org\/10.1093\/brain\/aws211.","journal-title":"Brain"},{"key":"8165_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-024-01429-4","volume":"16","author":"S Kang","year":"2024","unstructured":"Kang S, Jeon S, Lee YG, Ye BS. Alteration of medial temporal lobe metabolism related to Alzheimer\u2019s disease and dementia with lewy bodies. Alzheimers Res Ther. 2024;16:89. https:\/\/doi.org\/10.1186\/s13195-024-01429-4.","journal-title":"Alzheimers Res Ther"},{"key":"8165_CR64","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/mds.27945","volume":"35","author":"M Huber","year":"2020","unstructured":"Huber M, Beyer L, Prix C, Sch\u00f6necker S, Palleis C, Rauchmann BS, et al. Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Mov Disord. 2020;35:595\u2013605. https:\/\/doi.org\/10.1002\/mds.27945.","journal-title":"Mov Disord"},{"key":"8165_CR65","doi-asserted-by":"publisher","first-page":"e1182","DOI":"10.1212\/WNL.0000000000006212","volume":"91","author":"DW Dickson","year":"2018","unstructured":"Dickson DW, Heckman MG, Murray ME, Soto AI, Walton RL, Diehl NN, et al. APOE \u03b54 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91:e1182\u201395. https:\/\/doi.org\/10.1212\/WNL.0000000000006212.","journal-title":"Neurology"},{"key":"8165_CR66","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","volume":"115","author":"L Parkkinen","year":"2008","unstructured":"Parkkinen L, Pirttil\u00e4 T, Alafuzoff I. Applicability of current staging\/categorization of \u03b1-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115:399\u2013407. https:\/\/doi.org\/10.1007\/s00401-008-0346-6.","journal-title":"Acta Neuropathol"},{"key":"8165_CR67","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1212\/01.wnl.0000306697.48738.b6","volume":"70","author":"J Zaccai","year":"2008","unstructured":"Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology. 2008;70:1042\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000306697.48738.b6.","journal-title":"Neurology"},{"key":"8165_CR68","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun. 2020;11:2612. https:\/\/doi.org\/10.1038\/s41467-020-15701-2.","journal-title":"Nat Commun"},{"key":"8165_CR69","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/brain\/awae069","volume":"147","author":"N Okkels","year":"2024","unstructured":"Okkels N, Grothe MJ, Taylor J-P, Hasselbalch SG, Fedorova TD, Knudsen K, et al. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. Brain. 2024;147:2308\u201324. https:\/\/doi.org\/10.1093\/brain\/awae069.","journal-title":"Brain"},{"key":"8165_CR70","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/mds.29306","volume":"38","author":"C Tan","year":"2023","unstructured":"Tan C, Nawaz H, Lageman SK, Cloud LJ, Amara AW, Newman BT, et al. Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder. Mov Disord. 2023;38:474\u20139. https:\/\/doi.org\/10.1002\/mds.29306.","journal-title":"Mov Disord"},{"key":"8165_CR71","doi-asserted-by":"publisher","first-page":"107117","DOI":"10.1016\/j.parkreldis.2024.107117","volume":"127","author":"J Horsager","year":"2024","unstructured":"Horsager J, Andersen KB, Okkels N, Knudsen K, Skj\u00e6rb\u00e6k C, Van Den Berge N, et al. Correlation between dopaminergic and metabolic asymmetry in Lewy body disease \u2013 A dual-imaging study. Parkinsonism Relat Disord. 2024;127:107117. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107117.","journal-title":"Parkinsonism Relat Disord"},{"key":"8165_CR72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1212\/con.0000000000000309","volume":"22","author":"SN Gomperts","year":"2016","unstructured":"Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn). 2016;22:435\u201363. https:\/\/doi.org\/10.1212\/con.0000000000000309.","journal-title":"Continuum (Minneap Minn)"},{"key":"8165_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-017-0242-1","volume":"9","author":"J Kemp","year":"2017","unstructured":"Kemp J, Philippi N, Phillipps C, Demuynck C, Albasser T, Martin-Hunyadi C, et al. Cognitive profile in prodromal dementia with Lewy bodies. Alzheimers Res Ther. 2017;9:19. https:\/\/doi.org\/10.1186\/s13195-017-0242-1.","journal-title":"Alzheimers Res Ther"},{"key":"8165_CR74","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jalz.2008.04.005","volume":"4","author":"AM Hall","year":"2008","unstructured":"Hall AM, Moore RY, Lopez OL, Kuller L, Becker JT. Basal forebrain atrophy is a presymptomatic marker for Alzheimer\u2019s disease. Alzheimers Dement. 2008;4:271\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2008.04.005.","journal-title":"Alzheimers Dement"},{"key":"8165_CR75","doi-asserted-by":"publisher","first-page":"13249","DOI":"10.1038\/ncomms13249","volume":"7","author":"TW Schmitz","year":"2016","unstructured":"Schmitz TW, Nathan Spreng R, Weiner MW, Aisen P, Petersen R, Jack CR, et al. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer\u2019s pathology. Nat Commun. 2016;7:13249. https:\/\/doi.org\/10.1038\/ncomms13249.","journal-title":"Nat Commun"},{"key":"8165_CR76","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/brain\/awaa012","volume":"143","author":"S Fern\u00e1ndez-Cabello","year":"2020","unstructured":"Fern\u00e1ndez-Cabello S, Kronbichler M, Van Dijk KRA, Goodman JA, Spreng RN, Schmitz TW. Basal forebrain volume reliably predicts the cortical spread of Alzheimer\u2019s degeneration. Brain. 2020;143:993\u20131009. https:\/\/doi.org\/10.1093\/brain\/awaa012.","journal-title":"Brain"},{"key":"8165_CR77","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1089\/brain.2020.0937","volume":"13","author":"V Gupta","year":"2023","unstructured":"Gupta V, Booth S, Ko JH. Hypermetabolic Cerebellar Connectome in Alzheimer\u2019s Disease. Brain Connect. 2023;13:356\u201366. https:\/\/doi.org\/10.1089\/brain.2020.0937.","journal-title":"Brain Connect"},{"key":"8165_CR78","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2019.10.020","volume":"87","author":"BS Ye","year":"2020","unstructured":"Ye BS, Lee S, Yoo H, Chung SJ, Lee YH, Choi Y, et al. Distinguishing between dementia with Lewy bodies and Alzheimer\u2019s disease using metabolic patterns. Neurobiol Aging. 2020;87:11\u20137. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2019.10.020.","journal-title":"Neurobiol Aging"},{"key":"8165_CR79","doi-asserted-by":"publisher","first-page":"e14202","DOI":"10.1002\/alz.14202","volume":"21","author":"DA Wolk","year":"2025","unstructured":"Wolk DA, Nelson PT, Apostolova L, Arfanakis K, Boyle PA, Carlsson CM, et al. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimer\u2019s Dement. 2025;21:e14202. https:\/\/doi.org\/10.1002\/alz.14202.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8165_CR80","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/jon.12921","volume":"31","author":"M Aghourian","year":"2021","unstructured":"Aghourian M, Aumont \u00c9, Grothe MJ, Soucy JP, Rosa-Neto P, Bedard MA. FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. J Neuroimaging. 2021;31:1077\u201381. https:\/\/doi.org\/10.1111\/jon.12921.","journal-title":"J Neuroimaging"},{"key":"8165_CR81","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ana.26596","volume":"93","author":"NJ Ray","year":"2023","unstructured":"Ray NJ, Kanel P, Bohnen NI. Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson\u2019s Disease. Ann Neurol. 2023;93:991\u20138. https:\/\/doi.org\/10.1002\/ana.26596.","journal-title":"Ann Neurol"},{"key":"8165_CR82","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/brain\/awad226","volume":"146","author":"J Schumacher","year":"2023","unstructured":"Schumacher J, Kanel P, Dyrba M, Storch A, Bohnen NI, Teipel S, et al. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson\u2019s disease. Brain. 2023;146:4964\u201373. https:\/\/doi.org\/10.1093\/brain\/awad226.","journal-title":"Brain"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08165-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08165-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08165-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:25Z","timestamp":1793672965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08165-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":82,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8165"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08165-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Yonsei University Medical Center (4-2024-0544). The HCs provided written informed consent (IRB numbers: 4-2015-0551 and 4-2020-0737). Two hundred forty-seven patients with AD underwent FP-CIT PET scans with research funding (IRB number: 4-2018-0951). The need for informed consent from the remaining 198 patients with AD was waived because of the retrospective design of the study. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}